A number of studies suggest the neuroprotective role of gelsolin and potential of hypogelsolinemia as a therapeutic target in the development for therapeutic interventions in some neurological illnesses, including ischemic stroke [133], Alzheimer’s disease [134], multiple sclerosis [67], tick-borne encephalitis and Lyme neuroborreliosis [66], and subarachnoid hemorrhage [135]. Here, GSN is linked to multiple sclerosis.